Chronic Obstructive Pulmonary Disease | Unmet Need | Severe to Very Severe | US/EU | 2024

The severe to very severe chronic obstructive pulmonary disease (COPD) drug market is becoming increasingly crowded as several LAMAs, LABA/ICSs, LABA/LAMAs, and, most recently, LABA/LAMA/ICSs compete for shares of the maintenance drug space. Unfortunately, none of these agents can reverse disease progression or repair lung tissue; instead, current drug treatment focuses on improving breathing and reducing inflammation. Although inhaled medications are effective in reducing the burden of COPD by easing its symptoms, patients’ quality of life still suffers, and the disease remains one of the leading causes of death worldwide. Thus, significant unmet need remains for more-effective or disease-modifying therapies, especially for patients with more-severe COPD whose symptoms are not adequately controlled with available therapies.

QUESTIONS ANSWERED

• What are the key treatment drivers and goals for severe to very severe COPD?
• Which drug attributes are key influencers to pulmonologists’ prescribing decisions, which have limited impact, and which are hidden opportunities?
• How do current therapies such as Boehringer Ingelheim’s Spiriva, GlaxoSmithKline’s Anoro and Trelegy, and AstraZeneca’s Symbicort perform on these measures? What is pulmonologists’ perception of the performance of Advair compared with its generic, Mylan’s Wixela, on these measures?
• What are the prevailing areas of unmet need and opportunity in severe to very severe COPD?
• What trade-offs across different clinical / nonclinical attributes and price ranges are acceptable to U.S. and European pulmonologists for a hypothetical new COPD drug?

PRODUCT DESCRIPTION

Unmet Need provides quantitative insight into U.S. and European physicians’ perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 30 European pulmonologists fielded in February 2024

Key companies: GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Mylan

Key drugs: Advair / Seretide, Anoro, Spiriva, Stiolto / Spiolto, Symbicort, Trelegy, Wixela (generic)